Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Q3 2019 Earnings Conference Call - Final Transcript
Oct 30, 2019 • 04:30 pm ET
Ladies and gentlemen, thank you for standing by. Welcome to the Infinity Pharmaceuticals conference call to discuss the company's financial results for the third quarter 2019. My name is Bridget, and I'll be your operator for today's call. [Operator Instructions] Please be advised that this call is being recorded at Infinity's request.
Now I would like to introduce your host for today's call, Jayne Kauffman. Please go ahead.
Thank you, Bridget, and good afternoon, everyone. Welcome to today's call to discuss our recent business progress and review our third quarter 2019 financial results. With me here today are Adelene Perkins, Chief Executive Officer; Larry Bloch, President; and Dr. Jeff Kutok, our Chief Scientific Officer.
We will open up the call for Q&A following our remarks. The press release issued this afternoon details our results and is now available on our website at infi.com. Please note that during this call, we may make forward-looking statements about our future expectations and plans, including clinical development objectives, the therapeutic potential of our product candidates, our strategic plans and strategies and financial projections.
Our actual results may differ materially from what we project today due to a number of important factors, including the considerations described in the Risk Factors section of our annual report on Form 10-Q for the third quarter of 2019, and in other filings we make with the SEC. These forward-looking statements represent our views only as of today, and we caution you that we may not update them in the future, whether as a result of new information, future events or otherwise.
Now I would like to turn the call over to Adelene.
Thanks, Jayne, and thank you to everyone for joining us today. I'd like to start off today's call by highlighting the important clinical progress we have made this past quarter with the initiation of two additional clinical studies with IPI-549. We're very pleased by our advancement of IPI-549 into new indications, combinations and earlier lines of therapy as part of a thoughtful clinical development strategy designed to reveal the potentially transformative impact of reprogramming macrophages with IPI-549.
Successful clinical trial execution has been a key priority for Infinity in 2019, and we are very pleased that progress with MARIO-1 and the initiation of three new trials with IPI-549 over the past few months has enabled our announcement today of important milestones expected in 2020.
First, we expect to complete enrollment of MARIO-1 by year-end 2019 and to present clinical and translational data in 2020 from this Phase I/Ib study in collaboration with Bristol-Myers Squibb, evaluating IPI-549 in combination with Opdivo in patients with advanced solid tumors.
Second, in 2020 we expect to complete enrollment in and present data from MARIO-3, our Phase II study in collaboration with Roche/Genentech. MARIO-3 is a Phase II study of IPI-549 in combination with Tecentriq and Abraxane as a frontline treatment in patients with triple-negative breast cancer and in combination with Tecentriq and Avastin as a frontline treatment for patients with renal cell